ZYDUSLIFEZydus Lifesciences Ltd.
Zydus Lifesciences Q2 FY27 Results: Consolidated Net Profit ₹928 Crore on Total Income of ₹8,040 Crore
- Earnings
- Pharmaceuticals
Reviewed byRachit TripathiBlacklitt Research
Zydus Lifesciences (NSE: ZYDUSLIFE) reported consolidated total income of ₹8,040 crore and net profit of ₹928 crore for the quarter ended 30 Sep 2026, it said in a filing on 04 Nov 2026. Standalone total income was ₹3,647 crore and standalone net profit ₹715 crore for the same quarter.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹8,040 crore, up 29.0% YoY and down 1.0% QoQ
- Net profit: ₹928 crore, down 25.2% YoY and 8.2% QoQ
- EPS: ₹9.28 basic, against ₹12.53 a year earlier
- Finance costs: ₹187 crore, up 84.6% YoY
Standalone
The company on its own, without its subsidiaries
- Total income: ₹3,647 crore, up 6.9% YoY and 21.7% QoQ
- Net profit: ₹715 crore, down 38.2% YoY and up 110.4% QoQ
- EPS: ₹7.15 basic, against ₹11.49 a year earlier
- Dividends from subsidiaries: ₹22.0 crore in other income, against ₹419.8 crore a year earlier
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 8,040 | 6,232 | +29.0% | 8,123 | -1.0% | |
| Revenue from operations | 7,910 | 6,123 | +29.2% | 8,017 | -1.3% |
| Other income | 130 | 109 | +19.2% | 106 | +22.4% |
| 928 | 1,241 | -25.2% | 1,011 | -8.2% | |
| Profit before tax | 1,262 | 1,694 | -25.5% | 1,369 | -7.8% |
| Finance costs | 187 | 101 | +84.6% | 156 | +19.9% |
| Depreciation | 605 | 300 | +101.3% | 530 | +14.1% |
| Tax expense | 334 | 453 | -26.3% | 358 | -6.8% |
| Net profit margin | 11.54% | 19.91% | -8.37 pp | 12.44% | -0.90 pp |
| EPS, basic (₹) | 9.28 | 12.53 | -25.9% | 9.56 | -2.9% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Income grew faster than profit. Consolidated total income rose 29.0% year on year, while net profit fell 25.2% and profit before tax fell 25.5%.
Finance costs rose 84.6% to ₹187 crore, and depreciation rose 101.3% to ₹605 crore. Finance costs are 2.3% of total income this quarter, against 1.6% a year earlier. The filing reports that the consolidated results include Assertio Holdings from 16 Jun 2026, with provisional purchase price allocation figures; the company says the Assertio acquisition was for USD 23.50 per share in cash, about USD 166.4 million on a fully diluted basis.
They include a provision of ₹396 million for torrential rain damage at Ahmedabad, offset by an insurance claim receivable of ₹376 million, and a provision of ₹559 million for the settlement of class action antitrust lawsuits, together with a reversal of ₹33 million for severance at Assertio Holdings. Tax expense fell 26.3% to ₹334 crore, which is 26.5% of profit before tax.
The year-ago quarter is not in the same tax basis: the filing says tax for the year ended 31 Mar 2026 was computed under section 115BAA, and that current tax expenses are not comparable with previous reported periods. Profit attributable to owners is ₹925.5 crore, against ₹1,260.9 crore a year earlier.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 3,647 | 3,413 | +6.9% | 2,996 | +21.7% | |
| Revenue from operations | 3,482 | 2,871 | +21.3% | 2,872 | +21.2% |
| Other income | 165 | 542 | -69.6% | 124 | +33.1% |
| 715 | 1,157 | -38.2% | 340 | +110.4% | |
| Profit before tax | 962 | 1,444 | -33.4% | 456 | +111.1% |
| Finance costs | 101 | 114 | -10.9% | 103 | -1.6% |
| Depreciation | 155 | 136 | +14.3% | 152 | +2.3% |
| Tax expense | 248 | 287 | -13.7% | 116 | +113.3% |
| Net profit margin | 19.59% | 33.89% | -14.30 pp | 11.34% | +8.26 pp |
| EPS, basic (₹) | 7.15 | 11.49 | -37.8% | 3.38 | +111.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Standalone revenue from operations rose 21.3% to ₹3,482 crore, while other income fell 69.6% to ₹165 crore. Other income is 4.5% of standalone total income this quarter.
Standalone profit before tax fell 33.4% to ₹962 crore and net profit fell 38.2%, more than profit before tax. Tax expense was ₹248 crore, 25.7% of profit before tax. Finance costs were ₹101 crore, 2.8% of total income.
The standalone exceptional item for the quarter is ₹19 million, relating to a torrential rain provision of ₹373 million net of an insurance claim receivable of ₹354 million. Standalone net profit of ₹715 crore is ₹213 crore below consolidated net profit of ₹928 crore. The filing does not give the reason for the fall in standalone other income beyond the dividend figures.
Inference
The filing records the buyback of 8,730,158 equity shares, 0.87% of the total, on 18 Jun 2026 at an aggregate amount of ₹11,063 million including related expenses. It also records the completion of the acquisition of the API business of Sterling Biotech Limited on 2 Nov 2026, after a Business Transfer Agreement dated 17 Sep 2024. The filing does not state the consideration paid for that acquisition.
The filing does not say what the Assertio acquisition or the Sterling Biotech API business will add to future results; the company gives no outlook in this filing.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
